Repatha Shows Significant Benefits in Reducing Cardiovascular Risks and Mortality Rates

Amgen's Repatha has shown significant benefits in reducing cardiovascular risks and mortality rates, according to new data presented at the European Society of Cardiology Congress. The PCSK9 inhibitor was found to lower all-cause mortality by 20% in over 12,000 high-risk adults who had not had a prior heart attack or stroke.

The data also showed that Repatha reduced the risk of myocardial infarction by 36% and the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 29% in patients with high-risk diabetes and elevated LDL-C. However, Amgen's chief medical officer, Paul Burton, noted that despite these findings, only 42% of patients at high risk of a first cardiovascular event are taking a lipid-lowering therapy, and just 24% currently meet their LDL-C goal.

Burton attributed the slow uptake of Repatha to misconceptions about its use and access issues. However, he argued that comprehensive coverage and payment assistant plans should alleviate these concerns. The data from Vesalius-CV has led to a 'real sea change in the management of patients with high lipids and cardiovascular disease on primary prevention,' according to Burton.